Table 2.

Outcomes

	Pre-ASP	Post-ASP	P
Treatment duration, d	14 (10–16)	10 (7–14)	<.01
IV to PO, d	5 (4–6)	4 (3–5)	.046
CVC placementa	8 (15.7)	7 (8.1)	.17
Repeat blood cultures	34 (66.7)	38 (44.2)	.01
Length of stay, d	5 (3–7)	4 (3–8)	.54
Definitive therapyb
Beta-lactam/SMX PO	10 (19.6)	38 (44.2)	<.01
Beta-lactam/SMX IV	14 (27.5)	14 (16.3)
Fluoroquinolone PO	25 (49.0)	34 (39.5)
Fluoroquinolone IV	0 (0)	0 (0)
Other	2 (3.9)	0 (0)
30-d all-cause readmission	20 (39.2)	20 (23.3)	.047
30-d infection-related readmission	4 (7.8)	9 (10.5)	.61
30-d recurrence of bacteremia	0 (0)	2 (2.3)	.27
30-d mortality	0 (0)	2 (2.3)	.27

Data are presented as number (percentage) or median (interquartile range). Costs per case are not reported, per institutional policy.

Abbreviations: ASP, antimicrobial stewardship program; CVC, central venous catheter; IV, intravenous; PO, oral; SMX, sulfamethoxazole-trimethoprim.

^aCVC placement after onset of bacteremia.

^bFinal therapy of treatment.